During traditional medical training, students are often taught to manage patients’ symptoms by focusing on downstream effects—frequently employing pharmacological “silver bullets” to alleviate discomfort.
This approach may involve examining a patient’s lab results and then prescribing medications designed to normalize these values. Over time, however, clinical experience has revealed that simply adjusting lab numbers does not necessarily restore the underlying physiology or resolve the patient’s true health concerns.
Instead, key laboratory markers should guide healthcare providers toward uncovering and addressing root causes rather than treating the labs themselves.
[signup]
TSH and the Challenges of Thyroid Management
The complexities of thyroid care highlight the limitations of relying solely on lab values. A common approach suggests that a low TSH (thyroid-stimulating hormone) indicates hyperthyroidism, prompting treatments to reduce thyroid hormone production, while a high TSH suggests hypothyroidism, leading to interventions with synthetic T4 (levothyroxine). This model, though widespread, oversimplifies an intricate hormonal network.
The hypothalamic-pituitary-adrenal-gonadal-thyroid (HPATG) axis involves multiple feedback loops and interactions among hormones like thyroxine, cortisol, DHEA, testosterone, and estrogen.
Given this complexity, examining the thyroid in isolation overlooks how these hormones interrelate. Although there is still much to learn about the HPATG axis, assessing a comprehensive thyroid, adrenal, or sex hormone panel can offer a more accurate understanding of a patient’s condition.
Looking Beyond TSH Alone
Evaluating various hormone panels in combination with a patient’s clinical picture—especially for nonspecific symptoms such as fatigue—helps differentiate whether the root issue stems from thyroid function, adrenal health, or other hormonal imbalances.
For example, common hypothyroid symptoms include constipation, weight gain, depression, hair loss, swelling, and cold intolerance. Historically, an elevated TSH above the upper normal limit often led directly to a diagnosis of hypothyroidism, followed by testing total T4 levels.
If T4 was elevated, hyperthyroidism was suspected, often attributed to a pituitary adenoma. A normal T4 with an elevated TSH introduced the concept of “subclinical hypothyroidism,” while a low T4 typically confirmed hypothyroidism, prompting T4 replacement therapy.
Questioning Old Assumptions About TSH
Research by Dr. Dennis St. John O’Reilly scrutinized the history and evidence behind using TSH concentrations as a measure for T4 replacement. His analysis suggested that early reliance on TSH alone, dating back to the 1970s, was more theoretical than empirically validated.
He noted that diagnostic tests accept certain false positives and negatives, yet this nuance often is not applied to TSH. Instead, if a patient experiences hypothyroid symptoms but maintains a normal TSH, the issue is often attributed to the patient rather than reevaluating the test’s limitations.
Currently, little scientific data links biochemical thyroid tests directly to clinical signs and symptoms. Multiple factors influence TSH secretion beyond simple feedback from T4 and T3.
Although euthyroid sick syndrome or non-thyroidal illness is somewhat understood in critically ill patients, the myriad ways TSH, T4, T3, and reverse T3 fluctuate in other systemic illnesses remain poorly characterized.
Population Data: Rethinking Reference Ranges
The National Health and Nutrition Examination Survey III (NHANES), encompassing TSH, T4, and thyroid antibody evaluations in over 17,000 Americans (1988–1994), found that 80% of participants had TSH levels below 2.5 mIU/L.
The prevalence of Hashimoto’s thyroiditis, indicated by positive TPO antibodies, was lowest (<3%) when TSH values fell between 0.1–1.5 mIU/L for women and 0.1–2.0 mIU/L for men. Among individuals with TSH >20 mIU/L, more than 50% tested positive for TPO antibodies.
These findings suggest that reference limits for TSH may be skewed by individuals with subtle autoimmune thyroid conditions who test negative for TPO antibodies, and thyroglobulin antibodies were not assessed in that study.
A Broader Approach to Thyroid Evaluation
Historically, the standard approach to evaluating and treating thyroid disorders involved testing TSH and then, if abnormal, initiating treatment. If TSH was within reference ranges, the patient was often deemed “normal,” regardless of their clinical presentation.
This approach began to shift when clinicians started exploring additional markers, such as reverse T3. Initially less familiar, reverse T3 testing gained attention for its ability to offer insight into thyroid function at the cellular level.
Today, a more comprehensive thyroid panel is frequently employed. This panel may include TSH, total T4, free T4, total T3, free T3, and reverse T3, as well as thyroglobulin (Tg) when thyroid cancer is a concern, and TPO and Tg antibodies to identify autoimmune etiologies.
Given that micronutrients like selenium, zinc, iodine, and magnesium play critical roles in thyroid production and metabolism, measuring these cofactors is also recommended.
Considering Hyperthyroidism and Additional Markers
Hyperthyroidism, though less common than hypothyroidism, is often associated with Graves’ disease or thyroiditis. Symptoms may include heart palpitations, tachycardia, tremors, anxiety, heat intolerance, loose bowel movements, sweating, insomnia, and menstrual irregularities.
In these cases, additional labs specific to Graves’ disease, such as thyroid stimulating immunoglobulin (TSI) and thyrotropin receptor antibody (TRAb), are added to the comprehensive thyroid panel.
Reevaluating the Utility of T3 Measurement
The clinical value of evaluating serum T3 levels has historically been underemphasized. Current guidelines from the American Association of Clinical Endocrinologists (AACE), in collaboration with the American Thyroid Association (ATA), note that T3 (total or free) measurement in hypothyroidism offers limited utility.
This limitation arises because T3 levels can appear normal due to compensatory upregulation of type 2 iodothyronine deiodinase, as well as from systemic illnesses that reduce peripheral conversion of T4 to T3. Thus, low T3 levels can occur in the absence of intrinsic thyroid disease, complicating the interpretation of T3 in isolation.
The T3/Reverse T3 (rT3) Ratio
Examining the T3/rT3 ratio provides insight into cellular hormone bioavailability and tissue-level thyroid status. Research in elderly men found that elevated reverse T3 correlated with age and comorbidities. A low T3/rT3 ratio was associated with poorer physical performance scores, independent of chronic disease.
Conversely, lower free T4 levels were linked to better four-year survival, suggesting adaptive mechanisms that prevent excessive tissue catabolism. The authors concluded that T3/rT3 ratio is a useful marker of tissue hypothyroidism and diminished cellular functioning, a finding that challenges the stance that routine reverse T3 testing is unnecessary.
Another study examining T3/rT3 in individuals with and without type 2 diabetes (n=140) investigated the link between non-thyroid illness and cardiovascular events. Non-thyroid illness, often seen with normal TSH and T4 but low intracellular T3 and elevated reverse T3, can affect cardiovascular risk.
Subjects with type 2 diabetes and a history of cardiovascular events exhibited lower total T3, free T3, and T3/rT3 ratios, yet higher free T4 levels and similar TSH levels compared to controls. Inflammatory markers, like serum amyloid A, correlated positively with reverse T3 levels and inversely with T3/rT3 levels. These findings suggest that T3/rT3 levels may serve as an independent marker for cardiovascular event risk.
The Role of Thyroid Antibodies
Autoimmune thyroiditis is one of the most prevalent autoimmune conditions in the United States, potentially affecting up to 7-8% of the population (~24 million individuals). It is also the most common cause of hypothyroidism.
A retrospective cohort analysis of over 1,100 newly diagnosed Hashimoto’s patients and more than 4,600 non-Hashimoto’s controls found that women under 49 with Hashimoto’s had a significantly elevated risk of developing coronary heart disease (CHD) compared to controls.
This risk was not observed in men. After adjusting for comorbidities, Hashimoto’s remained an independent CHD risk factor, heightened further by coexisting hypertension or hyperlipidemia. Untreated Hashimoto’s or T4 treatment for less than one year carried the highest CHD risk.
[signup]
Addressing Autoimmunity and Environmental Factors
Autoimmune conditions are increasingly common, and environmental toxins are believed to contribute to their rise. Practitioners trained in Integrative and Functional Medicine often emphasize evaluating and addressing autoimmune etiologies.
Inflammation, oxidative stress, and immune dysregulation can promote both autoimmunity and thyroid resistance, necessitating higher levels of thyroid hormone for symptom resolution. The ultimate goal is to alleviate symptoms, enhance physiological function, and achieve hormonal homeostasis.
In conventional medicine, TSH has long been the primary marker for assessing thyroid function. However, exploring T4, T3, reverse T3, and antibody levels can provide a more comprehensive understanding of thyroid health and guide more effective patient care. This broader approach acknowledges that TSH alone may not capture the complexity of thyroid-related disorders and their impact on overall well-being.
%201.svg){kind=logo}
On December 11th, join Dr. Terry Wahls in a 
